Latest Industry Insights

This industry insight explores the findings from a comparative analysis of specific policies governing periodic updates to NBS panels in 30 European countries.

In this interview, Aiguo Zhang discusses some of the technologies that DiaCarta has developed within the liquid biopsy space and shares his thoughts on what the future may hold for the field.

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.

Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.

Unpicking our brain's complexity at a cellular level is a mammoth task. How do our genes, cells and electrical impulses come together to decode the world around us? At Boston University Assistant Professor Jerry Chen is trying to crack this code. In this interview, we speak to Chen about his study’s aims, findings and implications.

A new study demonstrated that lipidomic profiling can be used to predict the risk of developing Type 2 diabetes (T2D) and cardiovascular disease (CVD) years before disease onset. We spoke with study lead Professor Chris Lauber to find out more.

In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.

In this two-part interview series, Technology Networks delves deeper into the diagnostic odyssey many rare disease patients face and explores current efforts to develop improved therapies for these patients.

To learn more about the impact of manual inspection on urinalysis labs and how automated solutions such as the DxU Iris are helping to streamline workflows, Technology Networks spoke to Jose Crespo, senior director sales and marketing Europe, Beckman Coulter.

As primary care physicians continue to see an increasing number of patients with fatty liver disease, it is important for them to be able to effectively triage these patients to ensure the best possible care. In this opinion piece, Dr. Tram Tran, Chief Medical Officer of Glympse, discusses the importance of early intervention and highlights the urgent need for effective diagnostic strategies.